128 related articles for article (PubMed ID: 16386708)
21. The critical interaction of the metallopeptidase PHEX with heparan sulfate proteoglycans.
Barros NM; Nascimento FD; Oliveira V; Juliano MA; Juliano L; Loisel T; Nader HB; Boileau G; Tersariol IL; Carmona AK
Int J Biochem Cell Biol; 2008; 40(12):2781-92. PubMed ID: 18585473
[TBL] [Abstract][Full Text] [Related]
22. Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy.
Wang C; Poon S; Murali S; Koo CY; Bell TJ; Hinkley SF; Yeong H; Bhakoo K; Nurcombe V; Cool SM
Biomaterials; 2014 Aug; 35(25):6776-86. PubMed ID: 24854095
[TBL] [Abstract][Full Text] [Related]
23. On the structure, interactions, and dynamics of bound VEGF.
Horta BA; Cirino JJ; de Alencastro RB
J Mol Graph Model; 2008 Apr; 26(7):1091-103. PubMed ID: 18023381
[TBL] [Abstract][Full Text] [Related]
24. Novel cell adhesive glycosaminoglycan-binding proteins of Japanese encephalitis virus.
Wu SC; Chiang JR; Lin CW
Biomacromolecules; 2004; 5(6):2160-4. PubMed ID: 15530029
[TBL] [Abstract][Full Text] [Related]
25. Retardation of the unfolding process by single N-glycosylation of ribonuclease A based on molecular dynamics simulations.
Choi Y; Lee JH; Hwang S; Kim JK; Jeong K; Jung S
Biopolymers; 2008 Feb; 89(2):114-23. PubMed ID: 17937402
[TBL] [Abstract][Full Text] [Related]
26. Interactions of heparin/heparan sulfate with proteins: appraisal of structural factors and experimental approaches.
Powell AK; Yates EA; Fernig DG; Turnbull JE
Glycobiology; 2004 Apr; 14(4):17R-30R. PubMed ID: 14718374
[TBL] [Abstract][Full Text] [Related]
27. Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein.
Chandrasekaran V; Ambati J; Ambati BK; Taylor EW
J Mol Graph Model; 2007 Nov; 26(4):775-82. PubMed ID: 17560152
[TBL] [Abstract][Full Text] [Related]
28. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
Tammela T; He Y; Lyytikkä J; Jeltsch M; Markkanen J; Pajusola K; Ylä-Herttuala S; Alitalo K
Circ Res; 2007 May; 100(10):1468-75. PubMed ID: 17478733
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the recombinant rat 175-kDa hyaluronan receptor for endocytosis (HARE).
Weigel JA; Weigel PH
J Biol Chem; 2003 Oct; 278(44):42802-11. PubMed ID: 12933790
[TBL] [Abstract][Full Text] [Related]
30. Enhanced secretion of biologically active, non-glycosylated VEGF from Saccharomyces cerevisiae.
Kang WK; Lee MH; Kim YH; Kim MY; Kim JY
J Biotechnol; 2013 Apr; 164(4):441-8. PubMed ID: 23422691
[TBL] [Abstract][Full Text] [Related]
31. Probing conformational changes in orphan nuclear receptor: the NGFI-B intermediate is a partially unfolded dimer.
Garcia W; Figueira AC; de Oliveira Neto M; de Guzzi CA; Buzzá HH; Portugal RV; Calgaro MR; Polikarpov I
Biophys Chem; 2008 Oct; 137(2-3):81-7. PubMed ID: 18676081
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity.
Kawamura H; Li X; Harper SJ; Bates DO; Claesson-Welsh L
Cancer Res; 2008 Jun; 68(12):4683-92. PubMed ID: 18559514
[TBL] [Abstract][Full Text] [Related]
33. Structures of heparin-derived tetrasaccharide bound to cobra cardiotoxins: heparin binding at a single protein site with diverse side chain interactions.
Tjong SC; Chen TS; Huang WN; Wu WG
Biochemistry; 2007 Sep; 46(35):9941-52. PubMed ID: 17685633
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor binding protein-7 (IGFBP7) blocks vascular endothelial cell growth factor (VEGF)-induced angiogenesis in human vascular endothelial cells.
Tamura K; Hashimoto K; Suzuki K; Yoshie M; Kutsukake M; Sakurai T
Eur J Pharmacol; 2009 May; 610(1-3):61-7. PubMed ID: 19374835
[TBL] [Abstract][Full Text] [Related]
35. Accumulation of partly folded states in the equilibrium unfolding of ervatamin A: spectroscopic description of the native, intermediate, and unfolded states.
Nallamsetty S; Dubey VK; Pande M; Ambasht PK; Jagannadham MV
Biochimie; 2007 Nov; 89(11):1416-24. PubMed ID: 17658212
[TBL] [Abstract][Full Text] [Related]
36. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase.
Robinson CJ; Mulloy B; Gallagher JT; Stringer SE
J Biol Chem; 2006 Jan; 281(3):1731-40. PubMed ID: 16258170
[TBL] [Abstract][Full Text] [Related]
37. Dietary manganese affects the concentration, composition and sulfation pattern of heparan sulfate glycosaminoglycans in Sprague-Dawley rat aorta.
Kalea AZ; Lamari FN; Theocharis AD; Schuschke DA; Karamanos NK; Klimis-Zacas DJ
Biometals; 2006 Oct; 19(5):535-46. PubMed ID: 16937260
[TBL] [Abstract][Full Text] [Related]
38. Structural determinants of the unusual helix stability of a de novo engineered vascular endothelial growth factor (VEGF) mimicking peptide.
Diana D; Ziaco B; Colombo G; Scarabelli G; Romanelli A; Pedone C; Fattorusso R; D'Andrea LD
Chemistry; 2008; 14(14):4164-6. PubMed ID: 18384035
[No Abstract] [Full Text] [Related]
39. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
Lowe J; Araujo J; Yang J; Reich M; Oldendorp A; Shiu V; Quarmby V; Lowman H; Lien S; Gaudreault J; Maia M
Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704
[TBL] [Abstract][Full Text] [Related]
40. Endocytic function, glycosaminoglycan specificity, and antibody sensitivity of the recombinant human 190-kDa hyaluronan receptor for endocytosis (HARE).
Harris EN; Weigel JA; Weigel PH
J Biol Chem; 2004 Aug; 279(35):36201-9. PubMed ID: 15208308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
